Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
26.03(c) 25.61(c) 26.19(c) 26.22(c) 25.48(c) Last
686 141 912 759 1 010 660 792 757 1 233 890 Volume
+0.85% -1.61% +2.26% +0.11% -2.82% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -319 M - -
Net cash position 2021 506 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Sales 2022 3,58 M - -
Net income 2022 -351 M - -
Net cash position 2022 345 M - -
P/E ratio 2022 -11,4x
Yield 2022 -
Capitalization 3 950 M 3 950 M -
EV / Sales 2021 -
EV / Sales 2022 1 006x
Nbr of Employees 241
Free-Float 92,3%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which... 
More about the company
Ratings of Iovance Biotherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
10/25Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Web..
GL
10/18IOVANCE BIOTHERAPEUTICS : to Host Conference Call and Webcast to Highlight Data at Society..
AQ
10/12IOVANCE BIOTHERAPEUTICS : Corporate Presentation
PU
10/04IOVANCE BIOTHERAPEUTICS : to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL)..
AQ
09/29IOVANCE BIOTHERAPEUTICS : Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) i..
AQ
09/28IOVANCE BIOTHERAPEUTICS : Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) i..
AQ
09/28Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center in the ..
CI
09/23IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial State..
AQ
09/23IOVANCE BIOTHERAPEUTICS : Departure of Directors or Certain Officers; Election of Director..
PU
09/23IOVANCE BIOTHERAPEUTICS : Launches Clinical Supply of Tumor-Infiltrating Lymphocyte Cell T..
MT
09/23VC DAILY : Biotechs Seek New Skill Set From Scientists Entering Field
DJ
09/23Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL..
GL
09/23Iovance Biotherapeutics, Inc. Initiates Clinical Supply of Tumor-Infiltrating Lymphocyt..
CI
08/19IOVANCE BIOTHERAPEUTICS : Corporate Presentation
PU
08/06IOVANCE BIOTHERAPEUTICS : Goldman Sachs Adjusts Price Target for Iovance Biotherapeutics t..
MT
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
2020EN DIRECT DES MARCHES : Thales, Danone, Peugeot, Europcar, Ingenico, Disney, Nestlé...
2020Rester sur le marché ou le quitter, telle est la question
2020EN DIRECT DES MARCHES : Renault, Peugeot, Casino, Vivendi, Bourbon, Gaumont, Spirit, Ford...
2020L'accord commercial Chine / Etats-Unis se profile
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | IOVA | US4622601007 | MarketScreener
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 25,48 $
Average target price 40,38 $
Spread / Average Target 58,5%
EPS Revisions
Managers and Directors
Frederick G. Vogt President, CEO, Secretary & General Counsel
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Igor P. Bilinsky Chief Operating Officer
Sector and Competitors